Literature DB >> 16431839

Analysis and recommendations for agency action regarding nonsteroidal antiinflammatory drugs and cardiovascular risk.

.   

Abstract

On April 6, 2005, the Directors of the Office of New Drugs and the Office of Pharmacoepidemiology and Statistical Science at the U. S. Food and Drug Administration posted the following information on the FDA website pertaining to analysis and recommendations for FDA action regarding nonsteroidal anti-inflammatory drugs and cardiovascular risk.

Mesh：

Substances：

Year:  2005        PMID： 16431839

Source DB:  PubMed          Journal:  J Pain Palliat Care Pharmacother        ISSN： 1536-0288


  8 in total

1.  Pharmacovigilance: an active surveillance system to proactively identify risks for adverse events.

Authors:  Christopher Moses; Leo A Celi; John Marshall
Journal:  Popul Health Manag       Date:  2013-03-26       Impact factor: 2.459

2.  Safety and Efficacy of Indomethacin for Reducing Chest Tube Duration After Coronary Artery Bypass Grafting Surgery.

Authors:  Caitlin M Gibson; Brenton Hall; Hyanggi Irene Kwon; Sondra Davis; Darien Bradford; Meredith L Howard
Journal:  J Pharm Technol       Date:  2022-01-28

Review 3.  Celecoxib: a review of its use in the management of arthritis and acute pain.

Authors:  James E Frampton; Gillian M Keating
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 4.  Sumatriptan-naproxen fixed combination for acute treatment of migraine: a critical appraisal.

Authors:  Chaouki K Khoury; James R Couch
Journal:  Drug Des Devel Ther       Date:  2010-02-18       Impact factor: 4.162

5.  Antiplatelet therapy in acute coronary syndromes: current agents and impact on patient outcomes.

Authors:  Hussam M Tayeb; Adam J Nelson; Scott R Willoughby; Matthew I Worthley
Journal:  Patient Relat Outcome Meas       Date:  2010-12-30

6.  Decisions by regulatory agencies: are they evidence-based?

Authors:  Curt D Furberg
Journal:  Trials       Date:  2007-04-11       Impact factor: 2.279

7.  Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.

Authors:  N Bhala; J Emberson; A Merhi; S Abramson; N Arber; J A Baron; C Bombardier; C Cannon; M E Farkouh; G A FitzGerald; P Goss; H Halls; E Hawk; C Hawkey; C Hennekens; M Hochberg; L E Holland; P M Kearney; L Laine; A Lanas; P Lance; A Laupacis; J Oates; C Patrono; T J Schnitzer; S Solomon; P Tugwell; K Wilson; J Wittes; C Baigent
Journal:  Lancet       Date:  2013-05-30       Impact factor: 79.321

8.  Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the Phase 4 registry.

Authors:  Rachel E Sobel; Daniel J Lovell; Hermine I Brunner; Jennifer E Weiss; Paula W Morris; Beth S Gottlieb; Elizabeth C Chalom; Lawrence K Jung; Karen B Onel; Lisa Petiniot; Donald P Goldsmith; Kabita Nanda; Michael Shishov; Staci Abramsky; James P Young; Edward H Giannini
Journal:  Pediatr Rheumatol Online J       Date:  2014-07-16       Impact factor: 3.054
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.